TD Cowen Maintains Buy on Revvity, Raises Price Target to $175
TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $130 to $175.
Stocks · News reference
Revvity Rolls Out GSP T1D 3plex Kit
Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Barclays Maintains Equal-Weight on Revvity, Raises Price Target to $160
Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and raises the price target from $115 to $160.
William Blair Initiates Coverage On Revvity with Outperform Rating
William Blair analyst Matt Larew initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating.
Revvity Nears 52-Week High, but This Analyst Thinks Stock Can Climb Another 20%
William Blair initiates Revvity (RVTY) at Outperform, citing AI tailwinds, life sciences recovery, and potential 20%+ stock upside.